HRT Financial’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

HRT Financial’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-82,673	Closed	-$13K	–	3613
2024 Q4	$13K	Sell	82,673 -56,149	-40%	-$11.1K	﹤0.01%	2258
2024 Q3	$32K	Buy	+138,822	New	+$50.9K	﹤0.01%	2150
2023 Q3	–	Sell	-17,291	Closed	-$24K	–	3264
2023 Q2	$24K	Buy	+17,291	New	+$24.7K	﹤0.01%	2081
2021 Q2	–	Sell	-23,826	Closed	-$220K	–	3668
2021 Q1	$220K	Buy	+23,826	New	+$248K	﹤0.01%	2266

Other funds holding VIRX

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

HRT Financial's VIRX Position: Q1 2025 in Review

HRT Financial sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 82,673 shares — an estimated $13K sold.

HRT Financial first reported a position in VIRX in Q1 2021 and held it in 4 quarters. The position peaked at $220K in Q1 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

HRT Financial reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
HRT Financial sold 82,673 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $13K.
HRT Financial first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
HRT Financial's Viracta Therapeutics, Inc. Common Stock position peaked at $220K in Q1 2021.
7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.